Galmed & Tissue Dynamics Unveil Cardiac Fibrosis Pathway; Aramchol Reduces Fibrosis 4-Fold

Galmed Pharmaceuticals and Tissue Dynamics announced preclinical study results revealing a previously unknown metabolic pathway for cardiac fibrosis and heart failure. The study demonstrated that a combination of Galmed's Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold in human cardiac organoids, while preserving cardiac muscle integrity. This discovery supports the development of Aramchol for cardiac fibrosis, with a new patent application filed and preparations for IND-enabling activities underway. The collaboration aims to expand therapeutic opportunities for fibrotic diseases.